Fig. 4: Higher expression of ECD protein and mRNA in prostate cancer tissues correlate with short patient survival.

A Frequency and percentage of patient TMA samples assigned to each staining intensity. Representative IHC analysis of ECD expression in hyperplastic prostate tissue (B), and low-ECD (staining intensity 0, 1) and high-ECD expression (staining intensity 2, 3) in prostate cancer tissues (C) at magnification ×200. D Kaplan-Meier cumulative survival curve after surgery with patient tumors expressing low (staining intensities 0 or 1) or high ECD protein levels (staining intensities 2 or 3). P values were calculated with a log-rank test. E Case processing summary with number and percent of events used for the overall survival analysis in Panel D is enlisted. N = number of patients, N of events= number of patients where outcome was known and censored means where the patients’ outcome was unknown. F Kaplan-Meier plot for survival curve of prostate cancer patients shows short survival in patients with tumors expressing high ECD mRNA (n = 283) in comparison to low ECD mRNA (n = 201). P value is indicated in the KM plot. Mixed prostate adenocarcinoma (2022-v32) cohort (n = 484) of The Cancer Genome Atlas (TCGA) dataset was used to stratify ECD mRNA expression as high (>31.49 transcripts per million (TPM) and low (< 31.49 TPM). Analysis was performed using R2 Genomics platform.